Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Peter P., Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Szarek, Michael, Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman C.W., Sweeney, Michael, Ray, Kausik K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419281/
https://www.ncbi.nlm.nih.gov/pubmed/36039183
http://dx.doi.org/10.1016/j.ajpc.2022.100372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419281/
https://www.ncbi.nlm.nih.gov/pubmed/36039183
http://dx.doi.org/10.1016/j.ajpc.2022.100372

Ejemplares similares